Present and Future of Clinical Cardiovascular PET Imaging in Europe--a Position Statement by the European Council of Nuclear Cardiology (ECNC)

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2008 Jun 27

PMID 18581113

Citations 13

Authors

D Le Guludec

R Lautamaki

J Knuuti

J J Bax

F M Bengel

Affiliations

Soon will be listed here.

Abstract

This position statement was prepared by the European Council of Nuclear Cardiology and summarises the current and future potential of PET as a clinical cardiovascular diagnostic imaging tool. The first section describes how methodological developments have positively influenced the transition of PET from a research tool towards a clinical diagnostic test. In the second section, evidence in support of its superior diagnostic accuracy, its value to guide decision making and to predict outcome and its cost effectiveness is summarised. The third section finally outlines new PET-based approaches and concepts, which will likely influence clinical cardiovascular medicine in the future. The notion that integration of cardiac PET into healthcare systems and disease management algorithms will advance quality of care is increasingly supported by the literature highlighted in this statement.

Citing Articles

Automated concentration of [F]fluoride into microliter volumes.

Chao P, Lazari M, Hanet S, Narayanam M, Murphy J, van Dam R Appl Radiat Isot. 2018; 141:138-148.

PMID: 30243135 PMC: 6502507. DOI: 10.1016/j.apradiso.2018.06.017.

Research Progress on F-Labeled Agents for Imaging of Myocardial Perfusion with Positron Emission Tomography.

Mou T, Zhang X Molecules. 2017; 22(4).

PMID: 28358340 PMC: 6154634. DOI: 10.3390/molecules22040562.

Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM).

Sciagra R, Passeri A, Bucerius J, Verberne H, Slart R, Lindner O Eur J Nucl Med Mol Imaging. 2016; 43(8):1530-45.

PMID: 26846913 DOI: 10.1007/s00259-016-3317-5.

Validation of pixel-wise parametric mapping of myocardial blood flow with ¹³NH₃ PET in patients with hypertrophic cardiomyopathy.

Sciagra R, Passeri A, Cipollini F, Castagnoli H, Olivotto I, Burger C Eur J Nucl Med Mol Imaging. 2015; 42(10):1581-8.

PMID: 26121929 DOI: 10.1007/s00259-015-3101-y.

Molecular imaging of plaques in coronary arteries with PET and SPECT.

Sun Z, Rashmizal H, Xu L J Geriatr Cardiol. 2014; 11(3):259-73.

PMID: 25278976 PMC: 4178519. DOI: 10.11909/j.issn.1671-5411.2014.03.005.

References

Rudd J, Myers K, Bansilal S, Machac J, Rafique A, Farkouh M . (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. J Am Coll Cardiol. 2007; 50(9):892-6. DOI: 10.1016/j.jacc.2007.05.024. View

Pitkanen O, Nuutila P, Raitakari O, Ronnemaa T, Koskinen P, Iida H . Coronary flow reserve is reduced in young men with IDDM. Diabetes. 1998; 47(2):248-54. DOI: 10.2337/diab.47.2.248. View

Shaw L, Hendel R, Borges-Neto S, Lauer M, Alazraki N, Burnette J . Prognostic value of normal exercise and adenosine (99m)Tc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med. 2003; 44(2):134-9. View

Lewis P, Salama A . Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med. 1994; 35(10):1647-9. View

Patterson R, Churchwell K, Eisner R . Diagnosis of coronary artery disease in women: roles of three dimensional imaging with magnetic resonance or positron emission tomography. Am J Card Imaging. 1996; 10(1):78-88. View

Aarnoudse W, Botman K, Pijls N . False-negative myocardial scintigraphy in balanced three-vessel disease, revealed by coronary pressure measurement. Int J Cardiovasc Intervent. 2003; 5(2):67-71. DOI: 10.1080/14628840310003244. View

Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici P . Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003; 349(11):1027-35. DOI: 10.1056/NEJMoa025050. View

Bengel F . Atherosclerosis imaging on the molecular level. J Nucl Cardiol. 2006; 13(1):111-8. DOI: 10.1016/j.nuclcard.2005.11.003. View

Beanlands R, deKemp R, Smith S, Johansen H, Ruddy T . F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function. Am J Cardiol. 1997; 79(8):1092-5. DOI: 10.1016/s0002-9149(97)00054-4. View

10.

Martinez-Moller A, Zikic D, Botnar R, Bundschuh R, Howe W, Ziegler S . Dual cardiac-respiratory gated PET: implementation and results from a feasibility study. Eur J Nucl Med Mol Imaging. 2007; 34(9):1447-54. DOI: 10.1007/s00259-007-0374-9. View

11.

Bax J, Visser F, Blanksma P, Veening M, Tan E, Willemsen T . Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med. 1996; 37(10):1631-6. View

12.

Marwick T, Zuchowski C, Lauer M, Secknus M, Williams J, Lytle B . Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999; 33(3):750-8. DOI: 10.1016/s0735-1097(98)00642-1. View

13.

Jacklin P, Barrington S, Roxburgh J, Jackson G, Sariklis D, West P . Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. Ann Thorac Surg. 2002; 73(5):1403-9; discussion 1410. DOI: 10.1016/s0003-4975(02)03459-8. View

14.

Webb M, Chambers A, Al-Nahhas A, Mason J, Maudlin L, Rahman L . The role of 18F-FDG PET in characterising disease activity in Takayasu arteritis. Eur J Nucl Med Mol Imaging. 2004; 31(5):627-34. DOI: 10.1007/s00259-003-1429-1. View

15.

Di Carli M, Dorbala S, Curillova Z, Kwong R, Goldhaber S, Rybicki F . Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. J Nucl Cardiol. 2007; 14(6):799-809. DOI: 10.1016/j.nuclcard.2007.07.012. View

16.

Bax J, Veening M, Visser F, van Lingen A, Heine R, Cornel J . Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols. Eur J Nucl Med. 1997; 24(1):35-41. DOI: 10.1007/BF01728306. View

17.

Schoder H, Campisi R, Ohtake T, Hoh C, Moon D, Czernin J . Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol. 1999; 33(5):1328-37. DOI: 10.1016/s0735-1097(99)00010-8. View

18.

Brown T, Merrill J, Volokh L, Bengel F . Determinants of the response of left ventricular ejection fraction to vasodilator stress in electrocardiographically gated (82)rubidium myocardial perfusion PET. Eur J Nucl Med Mol Imaging. 2007; 35(2):336-42. DOI: 10.1007/s00259-007-0603-2. View

19.

Huisman M, Higuchi T, Reder S, Nekolla S, Poethko T, Wester H . Initial characterization of an 18F-labeled myocardial perfusion tracer. J Nucl Med. 2008; 49(4):630-6. DOI: 10.2967/jnumed.107.044727. View

20.

Hesse B, Lindhardt T, Acampa W, Anagnostopoulos C, Ballinger J, Bax J . EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 2008; 35(4):851-85. DOI: 10.1007/s00259-007-0694-9. View